Boston Scientific Corporation · NYSE:BSX
Boston Scientific — ACC 2026 Investor Update
17 slides from Boston Scientific's conference presentation, Mar 28, 2026
Slide 1: Relentless Innovation, Enduring Growth: ACC 2026 Investor Update
Relentless Innovation Enduring Growth ACC 2026 Investor Update March 28, 2026
Slide 2: Dr. Ken Stein, Chief Medical Officer
Relentless Innovation Enduring Growth Dr. Ken Stein| Senior Vice President & Chief Medical Officer
Slide 3: The Cardiovascular group
The Cardiovascular group Therapies that treat millions of patients worldwide each year Interventional Cardiology & Atrial Fibrillation (AF) Solutions Vascular Therapies (ICVT) Cardiac Rhythm Interventional Vascular Interventional Electro- WATCHMAN Management Oncology & physiology (EP) (WM) and Diagn
Slide 4: Driving evidence generation to fill clinical gaps
Driving evidence generation to fill clinical gaps Consistent cadence of data releases over long-range plan (LRP) & beyond Data release Product TAM supports: approval expanding 2026E 2027E 2028E+ HI-PEITHO FRACTURE (H1: 26) AGENT DCB STANCE EKOS vs. standard of Coronary IVL IDE to THRIVE AGENT DCB co
Slide 5: Dr. Michael R. Jaff, Chief Medical Officer, Vascular Therapies
Relentless Innovation Enduring Growth Dr. Michael R. Jaff| Vice President & Chief Medical Officer, Vascular Therapies
Slide 6: HI-PEITHO Clinical Trial
HI-PEITHO Clinical Trial Prospective, multicenter, global randomized controlled trial 544 patients with intermediate-risk pulmonary embolism (PE) at 59 sites in the U.S. and Europe ~1M people in the U.S. and Europe who are affected by PE annually1 EKOS Endovascular System + anticoagulation Anticoagu
Slide 7: Met primary efficacy endpoint
Met primary efficacy endpoint Patients treated with the EKOS system experienced 61% fewer primary endpoint events Major bleeding rate difference not statistically significant at 7- and 30- days between the two arms No intracerebral hemorrhagic events in either arm Data Presentation & Publication Mor
Slide 8: Dr. Brad Sutton, Chief Medical Officer, AF Solutions
Relentless Innovation Enduring Growth Dr. Brad Sutton| Chief Medical Officer, AF Solutions
Slide 9: CHAMPION-AF Clinical Trial
CHAMPION-AF Clinical Trial Largest trial comparing LAAC to NOACs as first-line therapy for stroke risk reduction in NVAF patients Patient Population: 3,000 Randomized at 141 sites globally • Patients with non-valvular atrial fibrillation and deemed suitable for oral anticoagulation • CHA2DS2-VASc sc
Slide 10: Met primary safety and efficacy endpoints
Met primary safety and efficacy endpoints Primary Efficacy Endpoint: Met Non-Inferiority Primary Safety Endpoint: Met Superiority Non-procedural bleeding (International Society on Thrombosis Cardiovascular death, stroke or systemic embolism and Haemostasis [ISTH] major and modified clinically releva
Slide 11: All clinically meaningful bleeds (procedural and non-procedural)
All clinically meaningful bleeds (procedural and non-procedural) 34% Reduction in ISTH bleeding (including procedural) at 36 months KM Event Rate ± 1.5 SE 11
Slide 12: Secondary endpoints underscore safety and net clinical benefit in WATCHMAN FLX arm
Secondary endpoints underscore safety and net clinical benefit in WATCHMAN FLX arm Secondary Safety Endpoint: Met Non-Inferiority Net Clinical Benefit Endpoint: Met Superiority ISTH major bleeding (procedural and non-procedural) Cardiovascular death, stroke, systemic embolism and non- procedural ble
Slide 13: CHAMPION-AF: All endpoints met
CHAMPION-AF: All endpoints met Efficacy: Achieved non-inferiority Safety: Achieved superiority OAC Adherence is real-world challenge Bleeding risk is a real concern for patients on OACs >87% Real-world >50% 45% data patients who were medication adherent in the NOAC arm increase in stroke risk for pa
Slide 14: Positive data positions market for meaningful expansion
Positive data positions market for meaningful expansion Today 2030E+ >$2.0B ~$6.0B+ Market Market 5 million AF patients indicated 20 million AF patients indicated 2026 2028E+ Published Literature & Labeling Update Guideline Evolution Expanded Reimbursement Clinical trial results + sub-analyses Posit
Slide 15: Fueling the future of LAAC innovation
Fueling the future of LAAC innovation 4th generation built on the WM platform designed to enhance seal & address complex anatomy 2026E ▪ Initiate Elite AF Clinical Trial * OPTION-EMEA ▪ Initiate OPTION-EMEA Clinical Trial ▪ Present SIMPLAAFY data 2027E ▪ ACUNAV Luxera 4D ICE Catheter U.S. approval w
Slide 16: Clinical Implications
Clinical Implications “WATCHMAN FLX left atrial appendage closure may be considered as an alternative to NOACs in a shared decision- making process with atrial fibrillation patients who are deemed suitable for long-term oral anticoagulation!” – Dr. Saibal Kar, CHAMPION-AF coprincipal investigator Ka
Slide 17: Q&A
Relentless Innovation Enduring Growth Q&A 17